Skip to main
ASMB

Assembly Biosciences (ASMB) Stock Forecast & Price Target

Assembly Biosciences (ASMB) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Assembly Biosciences is poised for future success, with a Phase 2 basket study on ABI-6250 targeting cholestatic liver diseases and promising results from their NTCP inhibition. Partnered with Gilead for further development and with regained rights to ABI-4334, the company has a strong financial position and will present additional data on ABI-6250 at the EASL Congress in 2026, indicating potential growth in the future. However, potential risks such as clinical development, Gilead's decision, and regulatory delays must be considered when evaluating the company's $0.9 billion valuation and potential future success.

Bears say

Assembly Biosciences is facing a significant amount of risk with its continued reliance on raising capital to fund operations, as well as potential dilution of current investors' holdings. Additionally, any delays or setbacks in the development and commercialization of its pipeline products could significantly impact the company's sales potential and valuation. While there is potential for data-rich catalysts in 2027, a data-light year in 2026 may not bode well for the company's overall prospects and its ability to generate profits until 2032. Furthermore, while the HDV program remains a top priority, there are also potential challenges in disrupting a historically low market for treatment, and even in a best-case scenario, the estimated peak annual revenues may not be enough to outweigh the risks involved.

Assembly Biosciences (ASMB) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assembly Biosciences (ASMB) Forecast

Analysts have given Assembly Biosciences (ASMB) a Buy based on their latest research and market trends.

According to 4 analysts, Assembly Biosciences (ASMB) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assembly Biosciences (ASMB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.